Lead Sponsor

Eli Lilly and Company

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Have a body mass index (BMI) of ≥30 kilogram per square meter (kg/m²) or ≥27 kg/m² and previously diagnosed with at least one of the following weight related comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease
•Have a history of at least 1 unsuccessful dietary effort to lose body weight

•Diabetes mellitus
•Change in body weight greater than 5 kg within 3 months prior to starting study
•Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity
•History of pancreatitis
•Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
•History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years

Related studies

NCT07351045 · Obesity or Overweight

NCT07543666 · Inflammation, Obesity (Disorder)

NCT07037459 · Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, and more

NCT07244458 · Dietary Change, Obesity & Overweight, and more

NCT07508241 · Obesity, Overweight and/or Obesity, and more

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities